989 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 989 shares of the biotechnology company’s stock, valued at approximately $88,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BPMC. Van ECK Associates Corp boosted its position in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 363 shares in the last quarter. Values First Advisors Inc. boosted its position in shares of Blueprint Medicines by 277.9% during the 4th quarter. Values First Advisors Inc. now owns 4,970 shares of the biotechnology company’s stock worth $433,000 after acquiring an additional 3,655 shares in the last quarter. Stephens Inc. AR acquired a new position in shares of Blueprint Medicines during the 4th quarter worth about $321,000. Jennison Associates LLC acquired a new position in shares of Blueprint Medicines during the 4th quarter worth about $31,417,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Blueprint Medicines by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,470 shares of the biotechnology company’s stock worth $1,175,000 after acquiring an additional 1,287 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BPMC. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Saturday. JMP Securities reissued a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their target price on Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Stephens reissued an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $123.83.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $92.25 on Friday. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The business’s 50 day moving average is $99.55 and its two-hundred day moving average is $94.39. Blueprint Medicines Co. has a 12-month low of $80.42 and a 12-month high of $121.90. The stock has a market capitalization of $5.90 billion, a price-to-earnings ratio of -85.42 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Research analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total value of $216,257.40. Following the completion of the sale, the chief operating officer now owns 71,657 shares in the company, valued at approximately $6,814,580.70. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,851 shares of company stock worth $4,984,696. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.